What is CGON's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 5.66B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CGON?

P/E (TTM) is n/a and 52-week range is $35.80 to $80.97 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CGON figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CGON?

The company profile lists revenue (TTM) near $6M, net income (TTM) near $-22.43B, EPS (TTM) near $-2.70 when available from the market-data feed. Figures are informational and may lag live markets.

Where is CG Oncology Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Irvine, California, US, 88.2M shares outstanding, ISIN US1569441009 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

CG Oncology Inc

$CGON

Health Care · Biotechnology

IR Run Scenarios

$63.82

+0.89%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 142 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Employees

142

Website

www.cgoncology.com/

IPO

2024-01-25

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)